All News
Orthotics in Rheumatoid Arthritis
Orthotics are cost-effective, externally applied devices designed to stabilize the joints and provide a conservative measure to alleviate joint pain and improve function. Options include therapeutic shoes, shoe inserts, hand splints/braces, wrist support and finger splints. This article reviews some of the indications on the use of orthotics in patients with RA.
Read Article
ACR Applauds Second Round of Medicare Drug Price Negotiations
d
ACR
The American College of Rheumatology applauded the announcement of additional drugs subject to pricing negotiations with the Centers for Medicare & Medicaid Services. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare rheumatologic conditions.
Read Article
Adalimumab Withdrawal in Uveitis Patients
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.
Read Article
🚨 Join us for the 7th Annual RheumNow Live 2/8 - 2/9 : Where Innovation Meets Impact in Rheumatology! 🚨
đź—“ 2025| In-Person & Virtual
✨ Why Attend?
- 🌟 Trailblazing research
- 🌍 World-class experts
- 🔥 Interactive learning
- 🤝 Unparalleled networking
- 📚… https://t.co/KvF8B3CrwO https://t.co/sqXWnKB3Va
Dr. John Cush RheumNow ( View Tweet)
QD Clinic- Past Diagnoses
When patients cling to a past diagnosis.
Features Dr. Jack Cush. QD Clinics - lessons from the clinic
Sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6
https://t.co/EB21WTDPJ2 https://t.co/JK4i2et8at
Dr. John Cush RheumNow ( View Tweet)
Weak Data (1.24.2025)
Dr. Jack Cush reviews the news and journal reports from https://t.co/V10S4oVFsv.
He features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025 and why she is an inspiration.
https://t.co/RKMvWVVnJA https://t.co/hmaPNZ9S5A
Dr. John Cush RheumNow ( View Tweet)
Quick study of Henoch-Schönlein Purpura (HSP) in Children: An Overview https://t.co/n4V0XfMYbA https://t.co/zJ5WVjdfYe
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - An Undiagnosed Autoinflammatory Patient
Autoinflammatory or Still's disease - does this matter?
Features Dr. Jack Cush. QD Clinics - lessons from the clinic
Sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/UimGBUZMeO https://t.co/fkAg9gK0Im
Links:
Dr. John Cush RheumNow ( View Tweet)
Open label trial of starting MTX in 11 uncontrolled gout pts previously Rx w/ IV pegloticase (PEG 2-27x) showed if gout pts failed PEG monotherapy, only 1/11 (9%) showed a good response to adding MTX w/ PEG. MTX must be started w/ PEG initiation to work https://t.co/aoBtyIRbQe https://t.co/RNe03O6Z1N
Dr. John Cush RheumNow ( View Tweet)
Febuxostat (ULORIC) is discontinued by the manufacturer in the USA. This week an FDA update on drug shortages list announced Uloric has been discontinued. Takeda sited dropping sales, generic competition, and CV safety concerns in the last decade. GENERIC febuxostat should still… https://t.co/QcUNCUFfvJ https://t.co/oBdwkcN177
Dr. John Cush RheumNow ( View Tweet)
Honoring Dr. Dafna Gladman
In December 2024, Dr. Dafna Gladman was appointed an officer of the Order of Canada by the Governor General. Established in 1967, the Order is one of Canada's top civilian honors, recognizing individuals whose achievements and service impact… https://t.co/Qv2uigX4sl https://t.co/uRsADqAZDq
Dr. John Cush RheumNow ( View Tweet)
Getting to Remission - Without Biologics
Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.… https://t.co/K1gUdEhk1n https://t.co/PHQafKPHpB
Dr. John Cush RheumNow ( View Tweet)
French cross-sectional study of pts on stable sc MTX x several yrs. Examined MTX polyglutamates (MTX-PGs) & disease activity in 34 RA pts (25 remission). + correlation between RA remission & high MTX-PG3 levels in pts w/ BMI <25. BMI may limit utility of PG3 levels… https://t.co/uped4oMkut https://t.co/4fmnDVHYYb
Dr. John Cush RheumNow ( View Tweet)
Palmar fasciitis & polyarthritis syndrome (PFPAS). JAMA case 50yoM w/ progressive hand swelling, stiffness, thickening, erythema, hepato-splenomegaly. Skin Bx dermal fibrous tissue. WBC 152k, LDH 889, lead to CML dx made by BM Fx (myeloid-erythroid ratio 21 w/ myeloblasts). +… https://t.co/xtHbzAioss https://t.co/RfMrfntFtb
Dr. John Cush RheumNow ( View Tweet)
Cardiovascular Risk in Cutaneous Lupus Erythematosus
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
https://t.co/QimKD9klM2 https://t.co/2Yb0tWoOB0
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 11 studies shows that curcumin (tumeric) can reduce pain, muscle damage and inflammation in athletes following vigorous physical exercise. "pre- and post-exercise curcumin consumption.. assoc w/ better outcomes in muscle recovery, pain & antioxidant capacity"… https://t.co/FZE2ugvvPK
Dr. John Cush RheumNow ( View Tweet)
Head-to-Head Clinical Trials
https://t.co/tt8uLuLiV2 https://t.co/BvWxCGGN5V
Dr. John Cush RheumNow ( View Tweet)
Lung Involvement in Still's Disease
A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.… https://t.co/rGYEgCeUDA https://t.co/fdUGvfU8HH
Dr. John Cush RheumNow ( View Tweet)
“Nothing in all the world is more dangerous than sincere ignorance and conscientious stupidity.”
- Martin Luther King
(Isnt that when someone says “I don’t know and I don’t care”) https://t.co/ZDwyyhX9XT
Dr. John Cush RheumNow ( View Tweet)
post hoc analysis of 4 registration trials of pegloticase, show rates of MACE and Thromboembolic Events were Infrequent (<1.5%; 35.4 events/1000 PY), similar to general gout population (31.7 events/1000 person-years) https://t.co/v6ZqtL4yB2 https://t.co/NA0j20Oew2
Dr. John Cush RheumNow ( View Tweet)